Article Text

Download PDFPDF
Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity
  1. M. J. KANDEL,
  2. A. LOEHR,
  3. P. HARTER,
  4. A. TRAUT,
  5. K. GNAUERT and
  6. A. DU BOIS
  1. Department of Gynecology and Gynecologic Oncology, Dr Horst-Schmidt-Kliniken, Wiesbaden, Germany
  1. Address correspondence and reprint requests to: Dr Michaela J. Kandel, Department of Gynecology and Gynecologic Oncology, Dr Horst-Schmidt-Kliniken, Ludwig-Erhard-Strasse 100, D-65199 Wiesbaden, Germany. Email: m.kandel{at}gmx.de

Abstract

Hypersensitivity reactions have been reported as limiting side effect in patients reexposed to carboplatin for relapsed gynecologic malignancy. This study analyzed the incidence, clinical features, management, and outcome of carboplatin-associated hypersensitivity reactions. We performed a retrospective study and analyzed medical records of all gynecological cancer patients treated with carboplatin in our institution from 2000 to 2003. No hypersensitivity reactions were observed in 171 patients during the first carboplatin-containing chemotherapy. All six carboplatin-associated hypersensitivity reactions occurred in 69 patients who were reexposed to carboplatin (9%). The median number of carboplatin cycles prior to hypersensitivity reaction was nine (range, 8–13). Cisplatin rechallenge was performed in five patients, and no hypersensitivity occurred. An increase in neurotoxicity (National Cancer Institute Common Toxicity Criteria grade 2) was documented in two patients who had residual neurotoxicity grade 1 due to prior taxane treatment. Cisplatinum rechallenge is a feasible strategy to overcome carboplatin hypersensitivity. However, close monitoring of neurotoxicity is necessary, particularly in patients with residual neurotoxicity due to prior platinum- and taxane-containing chemotherapy.

  • carboplatin
  • cisplatin
  • hypersensitivity reaction
  • ovarian cancer

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.